What question did this study set out to answer?

November 1, 1972Clinical Pharmacology & Therapeutics

Daunorubicin metabolism in acute nonlymphocytic leukemia

View Full Paper

Ask AI

Bookmark

Why the study?

What are the pharmacokinetics of daunorubicin and its metabolites in patients with acute nonlymphocytic leukemia?

Population

Patients with acute nonlymphocytic leukemia (n=8)

Design

Case_series

Authors

DHDavid H. HuffmanUniversity of Kansas Medical Center RBRobert S. BenjaminCardio-Oncology NBNicholas R. BachurUniversity of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

Discussion

Member takes

Implication

Case report PK data in leukemia should not guide dosing; leaves open metabolite monitoring and cardiac risk questions.

Key Points

To evaluate the pharmacokinetics of daunorubicin and its metabolites in patients with acute nonlymphocytic leukemia.
Analyzed plasma and urine samples from 8 patients for daunorubicin and its metabolites.
Measured half-lives of daunorubicin and daunorubicinol to assess variability in metabolism.
Mean plasma half-life of daunorubicin was 18.5 ± 4.86 hours; daunorubicinol was 26.7 ± 12.8 hours.
In 4 patients, daunorubicin and daunorubicinol had equal plasma half-lives, indicating individual variability.
The new metabolite D5 was the predominant fluorescent material in human heart tissue.

Structured PICO

What are the pharmacokinetics of daunorubicin and its metabolites in patients with acute nonlymphocytic leukemia?

Population

Patients with acute nonlymphocytic leukemia (n=8)

Intervention

Daunorubicin therapy

Outcome

Pharmacokinetic evaluation of daunorubicin and its metabolites (plasma half-life, tissue distribution)surrogate

Daunorubicinol plays a significant role in the pharmacodynamics of daunorubicin therapy, and a newly identified metabolite (D5) is predominant in the human heart.

Cite This Study

Huffman et al. (1972) studied this question.

synapsesocial.com/papers/6a200e67d47ed904550dbcb2 https://doi.org/10.1002/cpt1972136895

View Full Paper

Ask AI

Bookmark

Daunorubicin metabolism in acute nonlymphocytic leukemia

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Daunorubicin metabolism in acute nonlymphocytic leukemia

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider